• In late June 2026, Teradyne, Inc. was added to the NASDAQ‑100 and several Russell growth benchmarks while being removed from multiple value and defensive indices, marking a broad reclassification of the stock toward growth exposure.
• This simultaneous shift across major benchmarks reshapes how index funds and growth-oriented investors can access Teradyne, potentially amplifying the impact of its AI-focused revenue mix and raised guidance on portfolio positioning.
• Next, we’ll examine how Teradyne’s move into major growth indices, alongside its AI-driven revenue mix, influences the existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

Teradyne Investment Narrative Recap

To own Teradyne today, you need to believe its AI oriented test and automation business can keep attracting chip and data center spending while weathering trade, robotics and margin volatility. The recent shift into growth indices and the NASDAQ 100 mainly affects how capital tracks the stock, rather than changing the core near term catalyst around AI related test demand or the key risk from tariffs, trade policies and product mix swings.

The most relevant recent announcement here is Teradyne’s Q1 2026 update, where nearly 70% of revenue was AI related and management raised guidance. That concentration ties directly to why index providers now classify Teradyne as a growth name, but it also makes the company more exposed if AI infrastructure orders pause or if semiconductor test needs evolve in ways that pressure its margins.

Yet behind this growth focused reclassification, investors should be aware that Teradyne’s heavy AI dependence could quickly become a vulnerability if ...

Teradyne's narrative projects $6.8 billion revenue and $2.0 billion earnings by 2029. This requires 21.3% yearly revenue growth and about a $1.1 billion earnings increase from $854.1 million today.

Uncover how Teradyne's forecasts yield a $374.82 fair value, a 19% downside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were assuming only about 9 percent annual revenue growth and US$761.3 million of earnings by 2028, so you can see how views on Teradyne’s AI exposure and index driven spotlight may shift as new information arrives.

Explore 6 other fair value estimates on Teradyne - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Teradyne research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teradyne research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teradyne's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 42 companies with promising cash flow potential yet trading below their fair value.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.